Couple shots on goal here in the near term, mainly accelerating revenue based off existing sales of PCR
based COVID tests plus a new 12-min rapid antigen test coming in Feb. This is a turnaround play as the stock was previously priced for bankruptcy. Valuation should be 10-12x sales or $25-$30. Patience on this one
, its a slow grinder.